Payment overview · 2025
General Payments
$313.22
4 reported records · 4 companies
Healthcare provider profile · identity verified
Mark Hasenauer, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SEBASTIAN, FL · NPI 1255703252
Verified facts
What the public records show
CMS Open Payments records show Mark Hasenauer, PA received $313.22 in general payments during 2025 across 4 reported records.
AtriCure, Inc. accounted for 50.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $156.65 | 50.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $125.00 | 39.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.77 | 5.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14.80 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $313.22 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $156.65 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 67 |
| Lisinopril | Lisinopril | 212 | 62 |
| Alprazolam | Alprazolam | 201 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 44 |
| Gabapentin | Gabapentin | 148 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 45 |
| Omeprazole | Omeprazole | 134 | 50 |
| Tramadol Hcl | Tramadol Hcl | 133 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 37 |
| Metformin Hcl | Metformin Hcl | 124 | 43 |
| Losartan Potassium | Losartan Potassium | 115 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 114 | 38 |
| Meloxicam | Meloxicam | 88 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 22 |
| Trazodone Hcl | Trazodone Hcl | 74 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 26 |
| Sertraline Hcl | Sertraline Hcl | 58 | 17 |
| Methylprednisolone | Methylprednisolone | 56 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 22 |
| Eliquis | Apixaban | 54 | suppressed |
| Allopurinol | Allopurinol | 52 | 18 |
| Diazepam | Diazepam | 52 | 12 |
| Ezetimibe | Ezetimibe | 52 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | suppressed |
| Simvastatin | Simvastatin | 44 | 13 |
| Azithromycin | Azithromycin | 42 | 38 |
| Temazepam | Temazepam | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 32 |
| Montelukast Sodium | Montelukast Sodium | 39 | 13 |
| Buspirone Hcl | Buspirone Hcl | 37 | 15 |
| Glipizide | Glipizide | 37 | 13 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Famotidine | Famotidine | 34 | 16 |
| Furosemide | Furosemide | 33 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 11 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 15 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $313.22 · 4 records | AtriCure, Inc. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, Kerendia, Leqembi, TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error